All News
Decreasing immunogenicity, improving efficacy of pegloticase in gout
At #ACR20 three different medications are reviewed in different studies to decrease the immunogenicity of pegloticase – Methotrexate, Azathioprine and Mycophenolate Mofetil.
Read Article
Mitigating Immunogenicity When Using Uricase Therapies as ULT
ACR20 convergence highlights a shift in gout management and uric acid lowering therapy (ULT). The new biologics pegdriticase and pegloticase are associated with risk of immunogenicity and loss of biological effects.
Read Article
Poll results are in! Most would like to wait for a phase III before prescribing MMF with pegloticase in refractory gout. @RheumNow #ACR20 https://t.co/45MpFliDkE
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr McCormick presents on causal association between hyperuricaemia and diabetes. Insulin resistance causal for high urate. Target insulin resistance to prevent gout. @rheumnow #ACR20 Abstr#1472 https://t.co/OSr3ktIXSS
Richard Conway RichardPAConway ( View Tweet)
#Multimorbidity in #RheumaticDisease: Abs#1466:
-Highly prevalent across RA, PsA, gout & OA
-Highest burden in #gout
Important study highlighting need to recognise burden of MM in #rheumatology patients for holistic optimised management.
#ACR20 @RheumNow
https://t.co/esinnHoUME https://t.co/bApXfx7hOU
Mrinalini Dey DrMiniDey ( View Tweet)
Dr England presents on multimorbidity in RA, PsA, gout, and OA within RISE registry. Highly prevalent in all 4 but most pronounced in gout and RA. Critical to recognise and manage. @rheumnow #ACR20 Abstr#1466 https://t.co/XtwIfJnVXV
Richard Conway RichardPAConway ( View Tweet)
Study incl 1243 #SLE patients finds excess risk of #cardiovascular events is underestimated by CVD prediction tools- the underestimation may be increased in those with more severe disease activity.
Abs#1286 #ACR20 @RheumNow
https://t.co/6FZvxE02CF
Mrinalini Dey DrMiniDey ( View Tweet)
So excited to check out RheumNow’s ACR Mid-Meeting Recap live right now with Dr. Jack Cush (@rheumnow), Dr. Arthur Kavanaugh, Dr. Michale Pillinger, and Dr. Bella Mehta! #ACR20
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Crystal Arthritis and Gout Highlights at ACR: Dr. Nicola Dalbeth
Gout specialist Dr. Nicola Dalbeth from Aukland, New Zealand provides a preview perspective on crystal arthritis and gout studies and sessions at #ACR20.
https://t.co/QfVSpeVXlf https://t.co/cBwKF5P5eb
Links:
Dr. John Cush RheumNow ( View Tweet)
Reducing Immunogenicity of Pegloticase (RECIPE) w/ concomitant use of MMF in pts w/ refractory gout is a phase II double blind RCT that shows sustained serum urate lowering effect in addition to decrease in monthly rate of flares. #ACRbest #Abst0952 @RheumNow Practice changing? https://t.co/Z7GwCXZftE
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers https://t.co/fRB2zuKl5J #gout #uricosuric a novel uricosuric agent
Peter Nash drpnash ( View Tweet)
Based on RECIPE, how many of you will use MMF concomitantly with start of pegloticase in treating refractory gout patients? #ACR20 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Dr Khanna presents RECIPE RCT of MMF to reduce immunogenicity of pegloticase. Sustained urate response ≤6mg/dL at 24 weeks 68% with MMF compared to 30% in placebo. @rheumnow #ACR20 Abstr#952 #ACRbest https://t.co/64nN5AqK3W
Richard Conway RichardPAConway ( View Tweet)
Dr Merriman presents on role of diet in gout. It is minor, especially compared to urate lowering therapy. Average attributable fraction approximately 10-fold greater for ULT than following healthy-eating guidelines. @rheumnow #ACR20 Abstr#951 https://t.co/1tftswOEJq
Richard Conway RichardPAConway ( View Tweet)
Dr Cai presents risk of CVD in gout in study 450,000 patients. Gout was independently associated with an increased risk of CVD events HR = 1.24 for women; 1.21 for men. @rheumnow #ACR20 Abstr#950 #ACRbest https://t.co/089aKtN5a7
Richard Conway RichardPAConway ( View Tweet)
Evidence-Based Guidance for Optimizing Gout #ACR20 Reminding us of cardioprotective effect of anti-inflammatory gout management with colchicine. https://t.co/TmsrRd2vFD
Jilaine Bolek Berquist BolekBerqui ( View Tweet)
Is diet important in gout control? #ACR20 @rheumnow
Richard Conway RichardPAConway ( View Tweet)
@RheumNow #acr20 abs0665 claim based database stdy of pegloticase/immunomodulation coadministration trends: use of co-immunomodulation ⬆️ from 1.2%-3.9% 2015- 2018 to 15.0% in 2019. 86%start immunomodulator within 30 days of first peg infusion. MTX most commonly used
Olga Petryna DrPetryna ( View Tweet)
@RheumNow #acr20 abs0690 ph2a trial: potent reduction of sUA w/URAT1 inhibitor AA882. 100% of pts sUA levels < 6 mg/dL &63% pts < 5 mg/dL compared to febuxostat 50% & 13% respectively. Even more remarkable reduction w/ AA882+febuxostat. Mild to moderate SEs. https://t.co/XrDJXEoC1j
Olga Petryna DrPetryna ( View Tweet)
@RheumNow #acr20 abs0600 a case control stdy of 545 CHF exacerbate admissions: pts w/gout flares median LoS 10 d vs 6 d w/out flare or gout at all. log LoS w gout flare 2.41 ± 0.96 vs 1.77 ± 0.90 w/out, p < 0.0001. Prevention of gout flares in CHF pts of essence #ACRbest https://t.co/8xiHHYxvsC
Olga Petryna DrPetryna ( View Tweet)
